Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 165

Sort by

Sort Order Select

Journal Articles

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Jan H. Frenking, Christine Riedhammer, David N. Sedloev, Valentine Landrin, Mirco Julian Friedrich, Niels Weinhold, Martin K. Kortüm, Carsten Müller-Tidow, Hermann Einsele, Sandra Sauer, Leo Rasche, Marc S. Raab

Blood (2024) 144 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2024-210021

Published: 2024

Journal Articles

Specific U6 Small Nucleolar RNAs Are Present on the Surface of Primary AML Specimens and Are Accompanied By Short Fragments of Longer RNAs

Josephine Jagd Brysting, Christian Rohde, Laura Villacorta, Vladimir Benes, Simon Renders, Judith Zaugg, Carsten Müller-Tidow

Blood (2024) 144 (Supplement 1): 1339.

https://doi.org/10.1182/blood-2024-208198

Published: 2024

Journal Articles

Mapping Genotype to Phenotype in Clonal Hematopoiesis Uncovers Downregulated MHC-II Molecules in DNMT3A R882 - Mutant Hematopoietic Stem Cells

Patrick Stelmach, Dominik Vonficht, Anne Kathrin Merbach, Dawn S Lin, Sergi Beneyto-Calabuig, Marina Scheller, Aino-Maija Leppä, Florian Grünschläger, George S Vassiliou, Simon Haas, Lars Velten, Carsten Müller-Tidow, Andreas Trumpp

Blood (2024) 144 (Supplement 1): 1292.

https://doi.org/10.1182/blood-2024-203041

Published: 2024

Journal Articles

Tumor Reactive T Cells Drive Clinical Responses to Multiple Myeloma

Tim Robin Wagner, Niklas Kehl, Simon Steiger, Tamara Boschert, Michael Kilian, Kane A Foster, Hartmut Goldschmidt, Niels Weinhold, Steven A. Carr, Kwee Yong, Carsten Müller-Tidow, Karsten Rippe, Marc S. Raab, Michael Platten, Stefan B Eichmüller, Mirco Julian Friedrich

Blood (2024) 144 (Supplement 1): 1890.

https://doi.org/10.1182/blood-2024-210272

Published: 2024

Journal Articles

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2024-198861

Published: 2024

Journal Articles

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Blood (2024) 144 (Supplement 1): 4337.

https://doi.org/10.1182/blood-2024-209953

Published: 2024

Journal Articles

Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity

David N. Sedloev, Qian Chen, Julia M. Unglaub, Anita Schmitt, Carsten Müller-Tidow, Michael Schmitt, Tim Sauer

Blood (2024) 144 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2024-210286

Published: 2024

Journal Articles

A Venetoclax/Azacytidine Single-Cell RNA-Seq Resistance Signature (VARS) Predicts Response and Relapse in AML Patients

Anne Kathrin Merbach, Christian Rohde, Sergi Beneyto-Calabuig, Patrick Stelmach, Aino-Maija Leppä, Alexander Waclawiczek, Simon Renders, Michelle Lotze, Lars Velten, Andreas Trumpp, Tim Sauer, Rabia Shahswar, Michael Heuser, Carsten Müller-Tidow, Maike Janssen

Blood (2024) 144 (Supplement 1): 5744.

https://doi.org/10.1182/blood-2024-209706

Published: 2024

Journal Articles

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Blood (2024) 144 (Supplement 1): 1527.1.

https://doi.org/10.1182/blood-2024-198164

Published: 2024

Journal Articles

Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Blood (2024) 144 (Supplement 1): 708.

https://doi.org/10.1182/blood-2024-198638

Published: 2024

Journal Articles

Endothelial Dysfunction in Hematological Patients: Sublingual Microscopy, Hyperspectral Imaging, and Serum Endothelial Markers

Laura Simons, Muath Qadoura, Jule Buhl, Franziska Sunderer, Felix Korell, Ignatios Ikonomidis, Maximilian Dietrich, Silvia Seidlitz, Hans Vink, Lena Maier-Hein, Richard F. Schlenk, Carsten Müller-Tidow, Peter Dreger, Thomas Luft

Blood (2024) 144 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2024-205216

Published: 2024

Journal Articles

Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia

Blood (2024) 143 (22): 2284–2299.

https://doi.org/10.1182/blood.2023021640

Published: 2024

Includes: Supplemental data

Journal Articles

The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature

Anna Mathioudaki, Xizhe Wang, David Sedloev, Richard Huth, Aryan Kamal, Michael Hundemer, Yi Liu, Spyridoula Vasileiou, Premal Lulla, Carsten Müller-Tidow, Peter Dreger, Thomas Luft, Tim Sauer, Michael Schmitt, Judith B. Zaugg, Caroline Pabst

Blood (2024) 143 (13): 1269–1281.

https://doi.org/10.1182/blood.2023021815

Published: 2024

Includes: Supplemental data

Journal Articles

Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis

Blood (2023) 142 (19): 1633–1646.

https://doi.org/10.1182/blood.2023019758

Published: 2023

Includes: Supplemental data

Journal Articles

The Ig Superfamily Ligand B7H6 Subjects Activated T Cells to NK Cell Surveillance and Limits CAR T Cell Persistence

Blood (2023) 142 (Supplement 1): 4830.

https://doi.org/10.1182/blood-2023-190873

Published: 2023

Journal Articles

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Blood (2023) 142 (Supplement 1): 721.

https://doi.org/10.1182/blood-2023-186160

Published: 2023

Journal Articles

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 2236.

https://doi.org/10.1182/blood-2023-187273

Published: 2023

Journal Articles

Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence

Jan-Niklas Eckardt, Waldemar Hahn, Christoph Röllig, Sebastian Stasik, Uwe Platzbecker, Carsten Müller-Tidow, Hubert Serve, Claudia D Baldus, Christoph Schliemann, Kerstin Schäfer-Eckart, Maher Hanoun, Martin Kaufmann, Andreas Burchert, Christian Thiede, Johannes Schetelig, Martin Bornhäuser, Markus Wolfien, Jan Moritz Middeke

Blood (2023) 142 (Supplement 1): 2268.

https://doi.org/10.1182/blood-2023-179817

Published: 2023

Journal Articles

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Blood (2023) 142 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2023-189169

Published: 2023

Journal Articles

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Julia M. Unglaub, Berit Brinkmann, Qian Chen, David Sedloev, Peter-Martin Bruch, Carolin Kolb, Volker Eckstein, Yi Liu, Anita Schmitt, Simon Raffel, Michael Schmitt, Carsten Müller-Tidow, Junyan Lu, Sascha Dietrich, Tim Sauer

Blood (2023) 142 (Supplement 1): 5969.

https://doi.org/10.1182/blood-2023-181251

Published: 2023

NARROW

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Specific U6 Small Nucleolar RNAs Are Present on the Surface of Primary AML Specimens and Are Accompanied By Short Fragments of Longer RNAs

Mapping Genotype to Phenotype in Clonal Hematopoiesis Uncovers Downregulated MHC-II Molecules in DNMT3A R882 - Mutant Hematopoietic Stem Cells

Tumor Reactive T Cells Drive Clinical Responses to Multiple Myeloma

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity

A Venetoclax/Azacytidine Single-Cell RNA-Seq Resistance Signature (VARS) Predicts Response and Relapse in AML Patients

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Endothelial Dysfunction in Hematological Patients: Sublingual Microscopy, Hyperspectral Imaging, and Serum Endothelial Markers

Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia

The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature

Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis

The Ig Superfamily Ligand B7H6 Subjects Activated T Cells to NK Cell Surveillance and Limits CAR T Cell Persistence

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only